Clinical Trial Search

Primary: The Change From Baseline to the End of Treatment in the International Restless Legs Syndrome (IRLS) Rating Scale Score — -12.50; -12.54; -11.48; -9.93 units on a scale…

Primary: Change Lewis Score Index — -225 units on a scale

Primary: Percentage of Participants With Grade 3 and Grade 4 Alanine Aminotransferase (ALT) Abnormalities at Week 48 — 1.4; 1.5 Percentage of participants — p=0.4598

Primary: Safety Overview Within 30 Days in Participants Vaccinated With Menactra® — 0; 2 Participants

Primary: Whole Body Insulin Sensitivity During the Euglycemic Insulin Clamp — 3.2; 3.01; 3.4; 3.7 Mg. of glucose/kg body w./mUxl ins. — p=0.04

Primary: Mean Percentage of Cells Staining Positive for Annexin V Binding in Apoptosis — 8.95; 7.36; 8.45; 12.43 percentage of cells staining positive — p=0.308

Primary: Agitation in PACU — 15; 18; 4; 12 participants

Primary: Maximum Difference in Change From Baseline in ddQTcF Following a Single Dose of 33 mg/kg Deferiprone — 1.4; -1.6 milliseconds

Primary: Worst Severity Score of Overall Gastrointestinal (GI) Events, Modified Overall GI Symptom Scale (MOGISS) — 4.8 units on a scale

Primary: Hemoglobin — 1.2; 0.4; 1.1; 1.5 g/dL

Primary: Treatment Engagement — 36; 9 percentage of participants engaged

Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 0.4; 0.0 percentage of participants

Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -1.27; -1.51; -1.15 percentage of glycosylated haemoglobin — p=0.011

Primary: Number of Participants With Occlusion and Restenosis at One Year — 58; 56 participants

Primary: Maximum Perioperative Blood Glucose Level of 30 Minute Interval Measurements — 114.0; 108.0 mg/dL — p=0.87